EKF.LSE

EKF Diagnostics Holdings Plc

EKF.LSE, UK

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

https://www.ekfdiagnostics.com

Stock Price

GBp 0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EKF.LSE
stock
EKF.LSE

EKF Diagnostics (LON:EKF) Stock Crosses Below 200-Day Moving Average - Here's Why MarketBeat

Read more →
EKF.LSE
stock
EKF.LSE

EKF Diagnostics and Its Healthcare Operations Across FTSE AIM Landscape Kalkine Media

Read more →

Showing 2 of 7

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

3

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

24.80

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

166.96

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.71 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.36 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

17.57 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.13

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of EKF Diagnostics Holdings Plc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.005

Latest Release

Date

2025-06-30

EPS Actual

0.0043

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Strong Momentum(7)
Net Net
Possible Net-Net(4)
Quality
High Quality(7)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-06-30)

Revenue

£ 0

Cost Of Revenue

£ 0

Gross Profit

£ 0

Operating Expenses

£ 0

Operating Income

£ 0

Interest Expense

£ 0

Pretax Income

£ 0

Net Income

£ 0

Income Tax Expense

£ 0

EBITDA

£ 0

Total Other Income Expense Net

£ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

£ 0

Short Term Investments

£ 0

Receivables

£ 0

Inventories

£ 0

Total Current Assets

£ 0

Property Plant Equipment

£ 0

Total Assets

£ 0

Payables

£ 0

Short Term Debt

£ 0

Long Term Debt

£ 0

Total Liabilities

£ 0

Equity

£ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

£ 0

Depreciation

£ 0

Change In Working Capital

£ 0

Cash From Operations

£ 0

Capital Expenditures

£ 0

Cash From Investing

£ 0

Cash From Financing

£ 0

Net Change In Cash

£ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.